Episode
Questions for FDA
- Podcast
- Dr. John Campbell
- Published
- Sep 6, 2026
- Duration seconds
- 1203
- Processing state
not_requested- Canonical source
- https://traffic.megaphone.fm/VG4604255591.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/dr-john-campbell-7851784/episodes/questions-for-fda/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/dr-john-campbell-7851784/questions-for-fda.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Peter Doshi, senior editor, The BMJ The FDA should demand adequate, controlled studies with long term follow up, and make data publicly available, before granting full approval to covid-19 vaccines https://blogs.bmj.com/bmj/2021/08/23/does-the-fda-think-these-data-justify-the-first-full-approval-of-a-covid-19-vaccine/ Pfizer press release, 1 April, 2021 https://investors.pfizer.com/investor-news/press-release-details/2021/Pfizer-and-BioNTech-Confirm-High-Efficacy-and-No-Serious-Safety-Concerns-Through-Up-to-Six-Months-Following-Second-Dose-in-Updated-Topline-Analysis-of-Landmark-COVID-19-Vaccine-Study/default.aspx BNT162b2 is highly effective with 91.3% vaccine efficacy Data cut-off date was 13 March measured seven days through up to six months after the second dose Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine, (Published 28 July) https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1 Ongoing phase 3 covid-19 vaccine trial VE against COVID-19 was 91% (95% CI 89.0-93.2) through up to 6 months of follow-up, The current report provides updated efficacy analyses conducted on cases accrued up to March 13, 2021. Efficacy, an average decline of ~6% every 2 months FDA Approves First COVID-19 Vaccine, (23rd August) https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine Based on results from the clinical trial, the vaccine was 91% effective in preventing COVID-19 disease. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 202, (Published 18th August) https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e1.htm?s_cid=mm7034e1_w (NY data) Protection against infection July 25, 79.8% Age adjusted effectiveness against hospitalizations July 25, 91.9% to 95.3% During May 3–July 25…